Who are IQVIA Holdings Inc.'s main suppliers?

IQVIA Holdings Inc. (IQV) key suppliers include: U-S-BANK-TRUST-COMPANY-NATIONAL-ASSOCIATION, Medpace Holdings, Inc., Tempus AI, Inc.. View the full supplier network at chainsifter.com/chain/IQV.

Who are IQVIA Holdings Inc.'s major customers?

IQVIA Holdings Inc. (IQV) key customers include: BIOPHARMACEUTICAL-CUSTOMERS, LIFE-SCIENCE-CLIENTS, Fortrea Holdings Inc., Fortrea Holdings Inc., Medpace Holdings, Inc. and 13 more. View the full customer network at chainsifter.com/chain/IQV.

What sector is IQVIA Holdings Inc. in?

IQVIA Holdings Inc. (IQV) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

IQV Supply Chain: IQVIA Holdings Inc. Supplier List & 22 Relationships

3Suppliers

18Customers

1Debt Items

20Related Chains

IQVIA Holdings Inc. Suppliers

Ticker	Name	Confidence	Evidence
U-S-BANK-TRUST-COMPANY-NATIONAL-ASSOCIATION	U-S-BANK-TRUST-COMPANY-NATIONAL-ASSOCIATION	92%	The Notes were issued pursuant to an Indenture, dated June 11, 2026, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the Notes
MEDP	Medpace Holdings, Inc.	72%	Reciprocal relationship from MEDP graph: Reciprocal relationship from IQV graph: Reciprocal relationship from MEDP graph: Reciprocal relationship from IQV graph: Reciprocal relationship from MEDP gra…
TEM	Tempus AI, Inc.	72%	Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to t…

IQVIA Holdings Inc. Customers

Ticker	Name	Confidence	Evidence
BIOPHARMACEUTICAL-CUSTOMERS	BIOPHARMACEUTICAL-CUSTOMERS	90%	Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research, clinical trial and real-world research related services.
LIFE-SCIENCE-CLIENTS	LIFE-SCIENCE-CLIENTS	90%	Commercial Solutions provides mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the …
FTRE	Fortrea Holdings Inc.	72%	$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be…
FTRE	Fortrea Holdings Inc.	72%	Reciprocal relationship from FTRE graph: Reciprocal relationship from IQV graph: $ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.5…
MEDP	Medpace Holdings, Inc.	72%	Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiven…
SPGI	S&P Global Inc.	72%	Reciprocal relationship from SPGI graph: Reciprocal relationship from IQV graph: $ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.5…
SPGI	S&P Global Inc.	72%	$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be…
TEM	Tempus AI, Inc.	72%	Reciprocal relationship from TEM graph: Reciprocal relationship from IQV graph: Reciprocal relationship from TEM graph: Reciprocal relationship from IQV graph: Reciprocal relationship from TEM graph:…
TMO	Thermo Fisher Scientific Inc.	72%	ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to…
TMO	Thermo Fisher Scientific Inc.	72%	Reciprocal relationship from TMO graph: Reciprocal relationship from IQV graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IQV graph: ies, account for the majority of our re…
CHARLES-RIVER-LABORATORIES-INC-FORTREA-HOLDINGS-	CHARLES-RIVER-LABORATORIES-INC-FORTREA-HOLDINGS-	62%	$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be…
CMIC-HOLDINGS-CO-LTD	CMIC-HOLDINGS-CO-LTD	62%	ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to…
COGNIZANT-TECHNOLOGY-SOLUTIONS-DELOITTE-PHARMACE	COGNIZANT-TECHNOLOGY-SOLUTIONS-DELOITTE-PHARMACE	62%	ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to…
INFORMATION-TECHNOLOGIES	INFORMATION-TECHNOLOGIES	62%	ssments and other methods and resources to identify and manage cybersecurity risks. Our Integrated Information Security Framework ("IISF") defines minimum controls and safeguards used to safeguard pr…
INIZIO-SYNEOS-HEALTH-EPS-CORPORATION	INIZIO-SYNEOS-HEALTH-EPS-CORPORATION	62%	ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to…
MEDPACE-HOLDINGS-INC-S-P-GLOBAL-INC-DANAHER-CORP	MEDPACE-HOLDINGS-INC-S-P-GLOBAL-INC-DANAHER-CORP	62%	$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be…
PAREXEL-INTERNATIONAL-CORPORATION-PHARMACEUTICAL	PAREXEL-INTERNATIONAL-CORPORATION-PHARMACEUTICAL	62%	ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to…
PEER-GROUP	PEER-GROUP	62%	$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be…

IQVIA Holdings Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
IQV-DEBT	Debt stack $16.2B	90%	Market cache reports total debt of $16.2B.

IQVIA Holdings Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for IQVIA Holdings Inc..

IQVIA Holdings Inc. Ownership

Holder	Name	Confidence	Evidence
IQV-OWNER-DZ-BANK-AG-DEUTSCHE-ZENTRAL-GENO	DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	90%	13F overlay lists DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main as top holder; 1081 tracked holders.

IQVIA Holdings Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MEDP	Medpace Holdings, Inc.	100.00	1	['customer', 'supplier']
ARCC	Ares Capital Corporation	100.00	2
AZTA	Azenta, Inc.	100.00	2
TWST	Twist Bioscience Corporation	100.00	2
GH	Guardant Health, Inc.	100.00	2
PSO	Pearson plc	100.00	2
IDXG	Interpace Biosciences, Inc.	100.00	2
HON	Honeywell International Inc.	100.00	2
MYGN	Myriad Genetics, Inc.	100.00	2
FDS	FactSet Research Systems Inc.	100.00	2
BKH	Black Hills Corporation	100.00	2
RXRX	Recursion Pharmaceuticals, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
BHPLF	BHP Group Limited	100.00	2
CLLS	Cellectis S.A.	100.00	2
GRAL	GRAIL, Inc.	100.00	2
ICLR	ICON Public Limited Company	100.00	2
IMTX	Immatics N.V.	100.00	2
BTAI	BioXcel Therapeutics, Inc.	100.00	2
SOLV	Solventum Corporation	100.00	2

IQVIA Holdings Inc. Supply Chain